Maria Erazo, MD
Internal Medicine · Allentown, PANPI 1528145620
Payments from drug & device makers
Across 259 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$772
- Lilly USA, LLC$456
- Amgen$410
- OPKO Pharmaceuticals, LLC$373
- Boehringer Ingelheim$234
- plus $2K from 19 others
What the payments were for
- Consulting fees$3065%
- Food & beverage$5,41992%
- Education$1933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,718 |
| Novo Nordisk | 41 | $772 |
| Lilly USA, LLC | 30 | $456 |
| Amgen | 19 | $410 |
| OPKO Pharmaceuticals, LLC | 39 | $373 |
| Boehringer Ingelheim | 12 | $234 |
| Vifor Pharma, Inc. | 11 | $206 |
| Medtronic | 2 | $202 |
| Bayer | 5 | $190 |
| Amarin Pharma, Inc. | 12 | $171 |
| Xeris Pharmaceuticals, Inc. | 9 | $153 |
| Abbott | 3 | $153 |
| Otsuka America Pharmaceutical, Inc. | 3 | $137 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Insulet Corporation | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $79 |
| Corcept Therapeutics | 1 | $75 |
| Johnson & Johnson | 3 | $54 |
| Bardy Diagnostics, Inc. | 1 | $40 |
| Mannkind Corporation | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| GSK | 1 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$306
- Repatha$128
- FreeStyle Libre Pro$125
- JYNARQUE$125
- VOQUEZNA$125
- TARPEYO$125
- Kerendia$111
- Ozempic$110
- Minimed 670G System$106
How this compares
$5,918 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 424 | $517,177 |
| RayaldeeCalcifediol | 156 | $251,197 |
| KerendiaFinerenone | 284 | $248,522 |
| JardianceEmpagliflozin | 200 | $166,178 |
| FarxigaDapagliflozin Propanediol | 218 | $163,097 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 140 | $110,832 |
| Repatha SureclickEvolocumab | 111 | $84,597 |
| ProliaDenosumab | 49 | $83,134 |
| LinzessLinaclotide | 135 | $82,453 |
| VascepaIcosapent Ethyl | 167 | $77,111 |
| Praluent PenAlirocumab | 104 | $68,801 |
| RybelsusSemaglutide | 48 | $67,272 |
| Gvoke Hypopen 2-PackGlucagon | 85 | $60,818 |
| LokelmaSodium Zirconium Cyclosilicate | 57 | $59,149 |
| Metformin Er GastricMetformin Hcl | 19 | $50,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $456 | $547,007448 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $373 | $251,197156 claims |
| BayerKerendia | $190 | $248,522284 claims |
| AstraZenecaFarxiga, Lokelma | $1,718 | $222,246275 claims |
| Boehringer IngelheimJardiance, Synjardy | $234 | $209,745256 claims |
| Novo NordiskRybelsus, Ozempic, Novolog | $772 | $91,960103 claims |
| AmgenProlia | $410 | $83,13449 claims |
| Johnson & JohnsonXarelto | $54 | $24,71234 claims |
| MerckJanuvia | $14 | $12,76015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Allentown
- Joseph YozviakAllentown$1.1M
- Eric MuellerAllentown$585K
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.